TARA Stock Analysis: Buy, Sell, or Hold?
TARA - Protara Therapeutics, Inc. Common Stock
$4.22
-0.12 (-2.76%)
▼
5d:
-11.34%
30d:
-22.57%
90d:
-31.94%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When TARA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TARA is down 11.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TARA is down 11.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TARA is currently trading at $4.22, which is considered oversold relative to its 30-day fair value range of $4.62 to $5.36.
Technical Outlook: Technically, TARA is in a downtrend. The price is currently testing key support at $4.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TARA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.57 (+529.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TARA is in a downtrend. The price is currently testing key support at $4.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TARA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (19th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $26.57 (+529.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.62 -
$5.36
Company Quality Score
55/100
(HOLD)
Options IV Signal
19th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 19th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 529.7% below Wall St target ($26.57)
- WARNING: Recommendation downgraded due to -11.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.62 -
$5.36
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.71
(16.9%)
Support & Resistance Levels
Support Level
$4.30
Resistance Level
$5.09
Current Trend
Downtrend
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.75
Wall Street Target
$26.57
(+529.7%)
Share & Embed Analysis
Last updated: June 03, 2026 5:36 PM ET
Data refreshes hourly during market hours. Next update: 6:36 PM
Data refreshes hourly during market hours. Next update: 6:36 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TARA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Jacqueline Zummo
SELL
1134 shares
2026-04-08
Jacqueline Zummo
SELL
22598 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |
